Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 0-18592 MERIT MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Utah 87-0447695 (IRS Employer Identi ...

Merit Medical Systems, Inc. (NASDAQ:MMSI) Q3 2023 Earnings Conference Call October 26, 2023 5:00 PM ET Company Participants Fred Lampropoulos – Founder, Chairman and Chief Executive Officer Brian Lloyd – Chief Legal Officer and Corporate Secretary Raul Parra – Chief Financial Officer and Treasurer Conference Call Participants Michael Petusky – Barrington Research Steve Lichtman – Oppenheimer & Co Jayson Bedford – Raymond James Zachary Day – Canaccord Genuity Jim Sidoti – Sidoti & Co Mike Matson – Needham an ...

† A non-GAAP financial measure, representing constant currency revenue, organic. 5 5 In thousands, except percentages | --- | --- | --- | --- | --- | --- | |---------------------|-------|------------------------------------------|-------|-------|--------------| | | | Region Q3 2023 Q3 2022 $ Change % Change | | | CC % Change* | | U.S. | | $187,505 $164,571 $22,934 | | | 13.9% 14.3% | | | | | | | | | APAC | | 59,831 60,175 (344) -0.6% 3.2% | | | | | EMEA | | 55,206 52,060 3,146 6.0% 1.1% | | | | | | | | | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592 MERIT MEDICAL SYSTEMS, INC. Indicate by check mark whether the registrant has submitted electronically every In ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592 MERIT MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Utah 87-0447695 (State or other j ...

Merit Medical Investor Call July 25, 2023 Second Quarter 2023 Results Fred Lampropoulos Chairman and CEO | --- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592 MERIT MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Utah 87-0447695 (State or other ...

Merit Medical Systems, Inc. (NASDAQ:MMSI) Q1 2023 Earnings Call Transcript April 26, 2023 5:00 PM ET Company Participants Fred Lampropoulos - Chairman and Chief Executive Officer Raul Parra - Chief Financial Officer Brian Lloyd - Chief Legal Officer and Corporate Secretary Conference Call Participants Steve Lichtman - Oppenheimer Jayson Bedford - Raymond James Mike Matson - Needham & Company Jim Sidoti - Sidoti & Company Jason Bednar - Piper Sandler Michael Petusky - Barrington Research William Plovanic - C ...

Merit Medical Investor Call April 26, 2023 an 2 TRADEMARKS 3 m In thousands, except percentages 5 5 6 6 7 • constant currency revenue; • constant currency revenue, organic; • non-GAAP gross profit and margin; • non-GAAP operating income and margin; • non-GAAP net income; • non-GAAP earnings per share; and • free cash flow. Readers should consider non-GAAP measures used in this presentation in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP ...

Business Segments - The company operates through two segments: cardiovascular and endoscopy, with a focus on medical devices for vascular access and minimally invasive procedures [25]. - Cardiovascular segment includes product categories such as peripheral intervention, cardiac intervention, custom procedural solutions, and OEM [27]. - The endoscopy segment includes gastroenterology and pulmonary products, with a variety of kits and accessories for procedures [46]. Sales and Market Performance - U.S. sales accounted for 57% of net sales for the years ended December 31, 2022, 2021, and 2020 [55]. - In 2022, international sales grew by 7.4% compared to 2021, accounting for 43% of net sales, with China representing 13% of net sales at $149.3 million [56]. - The company achieved the highest annual revenue in its history in 2022, following growth in global sales as demand for products increased post-COVID-19 [58]. Product Development and Innovation - The company emphasizes rapid product development to meet customer needs, involving cross-departmental project teams for new product introductions [54]. - New product additions in 2022 included Prelude Roadster®, Sync EZ™, Safeguard Focus Cool™, and Scout BX™ [66]. - The company operates research and development facilities in California, Texas, Utah, Ireland, France, and Singapore, emphasizing innovation for continued growth [67]. Regulatory Compliance and Quality Standards - The company maintains a Corporate Integrity Agreement with the Office of Inspector General, requiring compliance with federal healthcare regulations [82]. - The company has received various ISO certifications for its facilities, ensuring adherence to international quality standards [68]. - Compliance with quality system regulations (QSR) is critical, as failure could lead to manufacturing shutdowns or product recalls, significantly impacting business operations [89]. Competition and Market Challenges - The company faces competition from larger firms such as Medtronic and Boston Scientific, but believes it holds a leading position in digital inflation technology [75]. - The company operates in a highly competitive market, facing competition from larger firms with greater resources [158]. - Consolidation in the healthcare industry has led to demands for price concessions, negatively impacting revenues [157]. Financial and Operational Risks - Elevated commodity and supply chain costs were experienced in 2022, with expectations for continued inflation in 2023 [149]. - The company faces challenges in passing increased costs onto customers due to the competitive nature of the healthcare industry [150]. - The company incurred substantial costs related to acquisitions and may face challenges in integrating acquired businesses, which could adversely affect financial results [166]. Legal and Regulatory Scrutiny - The company anticipates continued scrutiny from government authorities, which may increase compliance costs and expose it to litigation risks [188]. - The company is subject to various laws targeting fraud and abuse in the healthcare industry, with violations potentially leading to substantial fines and exclusion from healthcare programs [189]. - The company paid $18.7 million to resolve a DOJ investigation into past marketing practices, which included interest and fees, and is now operating under a Corporate Integrity Agreement (CIA) [187]. Data Privacy and Security - Privacy and data security compliance is increasingly complex, with potential fines for violations of laws such as GDPR and PIPL impacting operational costs [108]. - The company faces stringent privacy regimes, including GDPR in the EU, which imposes severe penalties for non-compliance and requires prompt notification of data breaches [109]. - Cyber-attacks could lead to unauthorized access to sensitive information, resulting in regulatory sanctions and damage to the company's reputation [222]. Employee and Talent Management - As of December 31, 2022, the company had 6,846 employees across approximately 40 countries, emphasizing the importance of attracting and retaining talent in the competitive medical device industry [126]. - The company achieved its eighth consecutive year of zero healthcare plan cost increases for U.S. employees participating in group healthcare plans, reflecting its focus on competitive health and wellness benefits [131]. - The company hired its first Director of Global Talent Management in 2021 to enhance global talent management programs, with a performance management program set to launch in 2023 [132]. Sustainability and Corporate Responsibility - The company has established a Corporate Sustainability Council to drive long-term Environment, Social, and Governance (ESG) goals across its enterprise [121]. - The company has identified sustainability opportunities, including programs to reduce waste and greenhouse gas emissions, as part of its business strategy [123]. - In 2022, the company supported humanitarian missions through product donations in five countries, including Haiti and Kenya [133].